Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
30 Sep 2019
Role of biomarkers, targeted therapy and tumour mutations in the landscape of bl...
Prof Petros Grivas and Dr Michiel Van der Heijden
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in bladder...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
30 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
Comment: Enfortumab vedotin is an effective therapy and important development fo...
Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak
18 Jun 2019
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for...
Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA
13 Jun 2019
Maintenance pembrolizumab vs placebo for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
13 Jun 2019
NILE: Should we give everything to patients with unresectable locally advanced o...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
13 Jun 2019
